Efficacy of rituximab in idiopathic membranous nephropathy and associated factors

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500109296

Enrollment

Unknown

Registered

2025-09-16

Start date

2024-12-02

Completion date

Unknown

Last updated

2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary membranous nephropathy

Interventions

Observation group:NA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Primary membranous nephropathy diagnosed by renal pathology; 2.Positive PLA2R antibody test and exclusion of secondary kidney disease.

Exclusion criteria

Exclusion criteria: 1. Secondary MN; 2. Patients with active infectious diseases.

Design outcomes

Primary

Measure	Time frame
Clinical efficacy rate;	—

Countries

China

Contacts

Public ContactQiu Shujuan

The Affiliated Hospital of Weifang Medical University

qiushujuan229@163.com+86 536 3081253

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026